The Journal of mHealth Vol 1 Issue 1 (Feb 2014) | Page 14

Industry News
Continued from page 8

medical communities.

“We focus on backing
ambitious entrepreneurs
who are using mobile
computing to unlock
opportunity and create
new markets,” said Kevin Talbot, co-founder
and managing partner of Relay Ventures.
“Walter’s vision for the
future of consumer
healthcare is profound
and Scanadu stands to
make a lasting impact
on an industry ripe for
disruption.”

“We are more determined than ever to
make the first medical
tricorder a reality,” said
Scanadu founder and
CEO Walter De Brouwer. “With the experience and expertise of
this group of investors
and advisors, we know
we’re in the right position to take our vision
all the way and put FDA
approved devices in the
hands of consumers.”

“Scanadu is right at the
heart of the next generation of computing
which combines mobility, sensors, cloud and
big data,” said Jerry
Yang, co-founder of
Yahoo! and founding
partner of Ame Cloud
Ventures. “I am bullish
on Scanadu and its potential to revolutionise
the way we think about
our health.”
In July of this year,
Scanadu closed a crowdfunding campaign on
Indiegogo that quickly
became the most funded campaign in the platform’s history, raising
more than $1.6 million.
Those who participated
in the campaign will
be a crucial part of the
company’s road to FDA
approval by taking part
on a voluntary basis
in a usability study for

12
February 2014

the Scanadu Scout™ in
2014.
Other participating investors in the Series
A round include Broe
Group, Mindful Investors and Redmile Group.
With this round, Scanadu has raised $14.7 million in funding to date.

MEDICAL
ADVISORY
BOARD AND
FIRST CLINICAL
TRIALS PAVE THE
WAY TO MARKET
Furthering the company
on its path to market,
Scanadu will conduct
its first clinical trials for
Scanadu Scout™ at the
Scripps
Translational
Science Institute (STSI).
Those studies will be
conducted as part of the
Wired for Health mobile
trial, which includes patients who live with diabetes, hypertension and
heart arrhythmia. This
first baseline study will

help design future controlled studies, and will
be designed to empower adults via a Scanadu
Scout™ to yield optimal
blood pressure.
“The era of digital
healthcare has arrived,”
said Dr. Eric Topol, director of the STSI and
chief academic officer for Scripps Health.
“We are excited to bring
Scanadu to Scripps to
further the potential of
this technology to improve lives.”
Scanadu’s newly established Medical Advisory
Board comprises leaders
with deep experience
from across the medical,
regulatory and research
fields. These advisors all
have a stake in advancing consumer healthcare
and will actively advise
Scanadu on long-term
strategy and facilitate the
sharing of knowledge
and innovation transfer
between Scanadu and
the larger research and

Scanadu is developing
a portfolio of products
that put the experience of an emergency
room visit in the palm
of your hand. Its first
device, the Scanadu
Scout™, is a vital sign
monitor that analyses,
tracks and trends your
vitals - temperature, respiratory rate, oximetry,
ECG, systolic blood
pressure and diastolic
blood pressure - in 10
seconds. The company
is also creating a disposable urine analysis testing platform, ScanaFlo,
which works with your
smartphone to offer a
complete urine analysis
test in minutes. Once
FDA approved, it could
also measure